Shen M, Kang Y. Cancer fitness genes: emerging therapeutic targets for metastasis. Trends Cancer. 2023;9(1):69–82. PMID: 36184492

Chen H, Zhan M, Liu J, Liu Z, Shen M, Yang F, Kang Y, Yin F, Li Z. Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction. J Med Chem. 2022;65(18):12188–12199. PMID: 36044768

Pérez-Núñez I, Rozalén C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Peña R, Montañés J, Albà M, Bonnin S, Ponomarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nat Cancer. 2022;3(3):355–370. PMCID: 5391692

Shen M, Wei Y, Kim H, Wan L, Jiang Y-Z, Hang X, Raba M, Remiszewski S, Rowicki M, Wu C-G, Wu S, Zhang L, Lu X, Yuan M, Smith H, Zheng A, Bertino J, Jin J, Xing Y, Shao Z-M, Kang Y. Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasis. Nat Cancer. 2022;3(1):43–59. PMCID: PMC8818087

Shen M, Smith H, Wei Y, Jiang Y-Z, Zhao S, Wang N, Rowicki M, Tang Y, Hang X, Wu S, Wan L, Shao Z-M, Kang Y. Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat Cancer. 2022;3(1):60–74. PMCID: PMC8818088

Shen M, Kang Y. Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. Genes Dev. 2020;34(23-24):1577–1598. PMCID: PMC7706714

Shen M, Xie S, Rowicki M, Michel S, Wei Y, Hang X, Wan L, Lu X, Yuan M, Jin J, Jaschinski F, Zhou T, Klar R, Kang Y. Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis. Cancer Res. 2021;81(4):1014–1025. PMCID: PMC8026491

Li W, Shen M, Jiang Y-Z, Zhang R, Zheng H, Wei Y, Shao Z-M, Kang Y. Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. Genes Dev. 2020;34(19-20):1310–1315. PMCID: PMC7528704

Fan H, Wang X, Li W, Shen M, Wei Y, Zheng H, Kang Y. ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP. Genes Dev. 2020;34(19-20):1359–1372. PMCID: PMC7528707

Shen M, Kang Y. Role Reversal: A Pro-metastatic Function of E-Cadherin. Dev Cell. 2019;51(4):417–419. PMID: 31743661

Shen M, Jiang Y-Z, Wei Y, Ell B, Sheng X, Esposito M, Kang J, Hang X, Zheng H, Rowicki M, Zhang L, Shih W, Celià-Terrassa T, Liu Y, Cristea I, Shao Z-M, Kang Y. Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell. 2019;35(1):64–80.e7. PMID: 30612941

Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med. 2018;12(4):426–439. PMID: 30097962

Shen M, Kang Y. pSTAT3 Reactive Astrocytes Promote Brain Metastasis. Trends Mol Med. 2018;24(9):733–735. PMID: 30029985

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun H, Coxon A, Lee B, Kang Y. Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 2017;32(6):731–747.e6. PMCID: PMC5729937